Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
113 CHF | +15.31% | +15.31% | +15.31% |
May. 02 | BTIG Adjusts Price Target on Zimmer Biomet to $139 From $138, Keeps Buy Rating | MT |
May. 02 | Transcript : Zimmer Biomet Holdings, Inc., Q1 2024 Earnings Call, May 02, 2024 |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
Weaknesses
- With a 2024 P/E ratio at 22.84 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- With an enterprise value anticipated at 3.65 times the sales for the current fiscal year, the company turns out to be overvalued.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+15.31% | 24.56B | - | ||
-3.77% | 184B | C+ | ||
-1.77% | 107B | C | ||
-1.43% | 67.52B | A | ||
+2.06% | 50.06B | B- | ||
+9.43% | 45.67B | B- | ||
+3.40% | 41B | B+ | ||
+3.04% | 26.73B | B | ||
+4.64% | 26.47B | A- | ||
+15.23% | 25.05B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ZBH Stock
- ZBH Stock
- Ratings Zimmer Biomet Holdings, Inc.